Drug Type Autologous CAR-T |
Synonyms- |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 modulators(CD22 modulators) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CD19 Expressing Malignancies | Phase 2 | US | 15 May 2019 | |
Chronic lymphocytic leukaemia refractory | Phase 2 | US | 15 May 2019 | |
Non-Hodgkin's lymphoma refractory | Phase 2 | US | 15 May 2019 | |
Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | US | 15 May 2019 | |
Recurrent Chronic Lymphoid Leukemia | Phase 2 | US | 15 May 2019 | |
Recurrent Non-Hodgkin Lymphoma | Phase 2 | US | 15 May 2019 | |
Refractory B Acute Lymphoblastic Leukemia | Phase 2 | US | 15 May 2019 |